Q4 2023 Holdings
Filed 2024-02-14 | 84 holdings | $8.8B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↑ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Biomea Fusion, Inc.(BMEA) | COM | 09077A106 | $30.6M | 2,108,949 | 0.3% |
| IGM Biosciences, Inc.(1K0) | COM | 449585108 | $30.7M | 3,691,011 | 0.3% |
| Bicycle Therapeutics plc(BCYC) | SPONSORED ADS | 088786108 | $32.4M | 1,790,390 | 0.4% |
| Sera Prognostics, Inc.(SERA) | CLASS A COM | 81749D107 | $32.5M | 5,434,399 | 0.4% |
| Edgewise Therapeutics, Inc.(EWTX) | COM | 28036F105 | $34.1M | 3,112,786 | 0.4% |
| Ideaya Biosciences, Inc.(IDYA) | COM | 45166A102 | $37.8M | 1,062,123 | 0.4% |
| Aerovate Therapeutics, Inc. | COM | 008064107 | $38.0M | 1,680,517 | 0.4% |
| Nurix Therapeutics, Inc.(NRIX) | COM | 67080M103 | $40.1M | 3,882,125 | 0.5% |
| Cerus Corporation(CERS) | COM | 157085101 | $42.1M | 19,477,339 | 0.5% |
| Prelude Therapeutics Inc.(PRLD) | COM | 74065P101 | $43.2M | 10,123,824 | 0.5% |
| Xenon Pharmaceuticals Inc.(XENE) | COM | 98420N105 | $45.8M | 993,679 | 0.5% |
| Kiniksa Pharmaceuticals, Ltd. | COM CL A | G5269C101 | $49.3M | 2,809,577 | 0.6% |
| Kodiak Sciences Inc.(KOD) | COM | 50015M109 | $52.6M | 17,310,490 | 0.6% |
| Akero Therapeutics, Inc.(AKRO) | COM | 00973Y108 | $55.3M | 2,368,378 | 0.6% |
| Denali Therapeutics Inc.(DNLI) | COM | 24823R105 | $56.0M | 2,607,196 | 0.6% |
| argenx SE(ARGX) | SPONSORED ADR | 04016X101 | $57.5M | 151,215 | 0.7% |
| BioCryst Pharmaceuticals, Inc.(BCRX) | COM | 09058V103 | $60.7M | 10,126,176 | 0.7% |
| Immatics N.V.(IMTX) | SHS | N44445109 | $61.5M | 5,838,853 | 0.7% |
| Cerevel Therapeutics Holdings, Inc.(CERE1EUR) | COM | 15678U128 | $67.8M | 1,600,000 | 0.8% |
| Ultragenyx Pharmaceutical Inc.(RARE) | COM | 90400D108 | $70.1M | 1,466,547 | 0.8% |
| Entrada Therapeutics, Inc.(TRDA) | COM | 29384C108 | $73.4M | 4,865,819 | 0.8% |
| Replimune Group, Inc.(REPL) | COM | 76029N106 | $80.5M | 9,545,336 | 0.9% |
| Roivant Sciences Ltd.(ROIV) | SHS | G76279101 | $85.3M | 7,593,024 | 1.0% |
| AbCellera Biologics Inc.(ABCL) | COM | 00288U106 | $130.8M | 22,909,753 | 1.5% |
| Invitae Corporation | Notes 1.5% 4/1/2028 | 46185LAD5 | $131.2M | $300,000,000 | 1.5% |
| Revolution Medicines, Inc.(RVMD) | COM | 76155X100 | $147.7M | 5,148,657 | 1.7% |
| Kymera Therapeutics, Inc.(KYMR) | COM | 501575104 | $152.7M | 5,995,928 | 1.7% |
| Immunocore Holdings plc(IMCR) | ADS | 45258D105 | $172.2M | 2,520,731 | 2.0% |
| Mirati Therapeutics, Inc.(MRTXEUR) | COM | 60468T105 | $242.1M | 4,121,440 | 2.8% |
| Rhythm Pharmaceuticals, Inc.(RYTM) | COM | 76243J105 | $294.1M | 6,398,365 | 3.3% |
| Madrigal Pharmaceuticals, Inc.(MDGL) | COM | 558868105 | $455.8M | 1,969,798 | 5.2% |
| Acadia Pharmaceuticals Inc.(ACAD) | COM | 004225108 | $1.3B | 42,864,612 | 15.3% |
| BeiGene, Ltd.(ONC) | SPONSORED ADR | 07725L102 | $1.9B | 10,568,897 | 21.7% |
| Incyte Corporation(INCY) | COM | 45337C102 | $2.3B | 36,179,122 | 25.8% |